LivaNova launches next-gen ICT, CRT-Ds in US

LivaNova (NSDQ:LIVN) said today it is launching its next-gen Platinium implantable cardiac defibrillators and cardiac resynchronization therapy devices in the U.S.

The next-gen devices include improved longevity and lower energy consumption, with service life projected over 14 years for single-chamber ICDs, 13 years for dual-chamber ICDs and 10 years for CRT-D devices, LivaNova said.

“The technology we have developed will provide U.S. physicians and patients a broader range of devices offering the longest projected longevity of any on the market. Platinium addresses the medical community requests in closing the gap between patient life expectancy and device service life.  LivaNova is committed to health innovation that matters and Platinium devices reaffirm this commitment,” LivaNova CRM GM & veep Benoît Clinchamps said in a press release.

The U.K.-based company’s Platinium devices also feature the Parad+ arrhythmia discrimination algorithm and SafeR pacing mode to preserve natural heart conduction.

“Increasing the longevity of ICD and CRT-D devices is crucial for patients to avoid early replacement surgeries, which carry risks of complications and increase the cost of care. Longevity needs to be a primary consideration when selecting a device for a patient.  I welcome the launch of LivaNova’s Platinium devices.  They represent a significant improvement in medical technology, combining superb arrhythmia detection and discrimination algorithms with excellent battery longevity,” Dr. Steven Kutalek of Philadelphia’s Drexel University College of Medicine said in prepared remarks.

The post LivaNova launches next-gen ICT, CRT-Ds in US appeared first on MassDevice.

from MassDevice http://ift.tt/2ddY7js